Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.
Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23.
Brain. 2015.
PMID: 25805645
Free PMC article.
Clinical Trial.
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease.
Grolez G, Moreau C, Sablonnière B, Garçon G, Devedjian JC, Meguig S, Gelé P, Delmaire C, Bordet R, Defebvre L, Cabantchik IZ, Devos D.
Grolez G, et al. Among authors: meguig s.
BMC Neurol. 2015 May 6;15:74. doi: 10.1186/s12883-015-0331-3.
BMC Neurol. 2015.
PMID: 25943368
Free PMC article.
Clinical Trial.
Item in Clipboard
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group.
Adams D, et al.
Lancet Neurol. 2021 Jan;20(1):49-59. doi: 10.1016/S1474-4422(20)30368-9. Epub 2020 Nov 16.
Lancet Neurol. 2021.
PMID: 33212063
Clinical Trial.
Item in Clipboard
Cite
Cite